Advertisement
U.S. markets closed

Viatris Inc. (VTRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.76-0.18 (-1.51%)
At close: 04:00PM EDT
11.71 -0.05 (-0.43%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close11.94
Open11.87
Bid12.00 x 3100
Ask12.06 x 3000
Day's Range11.72 - 11.94
52 Week Range8.74 - 13.62
Volume8,268,546
Avg. Volume10,355,431
Market Cap13.966B
Beta (5Y Monthly)1.14
PE Ratio (TTM)235.20
EPS (TTM)0.05
Earnings DateMay 06, 2024 - May 10, 2024
Forward Dividend & Yield0.48 (4.08%)
Ex-Dividend DateMar 08, 2024
1y Target Est14.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-35% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for VTRS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Viatris Inc.
    Daily – Vickers Top Buyers & Sellers for 03/18/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    16 hours agoArgus Research
View more
  • Motley Fool

    Is Viatris a Great Dividend Stock or Just a Value Trap?

    Investors can collect a high yield with Viatris, but is it a risky payout to rely on?

  • Motley Fool

    2 Dirt Cheap Dividend Stocks to Buy and Hold

    These companies aren't popular on the market right now, but income investors will like them.

  • Reuters

    UPDATE 2-US FDA declines to approve Viatris's injection for multiple sclerosis

    The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition multiple sclerosis (MS), the companies said on Monday. The companies were reviewing the content of the health regulator's so called complete response letter (CRL) and would soon determine the appropriate next steps, they said, without disclosing further details. Mapi Pharma did not immediately respond to Reuters requests for additional details on the contents of the CRL, which indicates that an application would not be approved in its present form and requires more information.